



Nessa Carey (left) has joined CellCentric (Cambridge, UK) as director of research. Dr. Carey was most recently head of biology at TopoTargets, and previously served as head of molecular biology and pharmacology at Vernalis from 2001 to 2004.

CellCentric also announced a number of changes to its board of directors: **Barrie Ward** has been appointed nonexecutive chairman, and **Sue Foden** becomes a nonexecutive director. As chief executive officer of KuDos Pharmaceuticals, Dr. Ward led the company from its inception through to its acquisition by AstraZeneca in December

2005. He also serves as chairman of Avant Immunotherapeutics and Onyvax. Dr. Foden is a trustee of the Institute of Cancer Research and chairs its intellectual property subcommittee. She was previously at Celltech, the Cancer Research Campaign (now Cancer Research UK) and Merlin BioSciences.

Richard Chin has been appointed to the position of president and CEO of OXiGENE (Waltham, MA, USA), replacing **Frederick Driscoll**. Dr. Chin, a current member of OXiGENE's board of directors, was most recently senior vice president and head of global development for Elan Corp., with worldwide responsibility for clinical development, regulatory, biostatistics, quality assurance/compliance, chemistry manufacturing and control, safety and medical affairs.

Earl M. 'Duke' Collier, Jr. has been elected to deCODE Genetics' (Reykjavik, Iceland) board of directors. Mr. Collier is an executive vice president at Genzyme and has previously served as president of Vitas Healthcare, partner at the law firm of Hogan and Hartson, and deputy administrator of the Health Care Finance Administration (now CMS) in the US Department of Health and Human Services.

Generex Biotechnology (Toronto, ON, Canada) has appointed **Jaime Davidson** as a consultant medical director. Dr. Davidson is the president of Endocrine and Diabetes Associates of Texas, based at the Medical City Dallas Hospital complex, and a clinical associate professor of internal medicine at University of Texas Southwestern Medical Center. He has served as an advisor to the US Food and Drug Administration on the endocrinology and metabolism advisory board.

Aastron Biosciences (Ann Arbor, MI, USA) has announced the appointment of **George W. Dunbar, Jr.** as president, CEO and a member of its board of directors. Mr. Dunbar has more than 25 years of experience in the healthcare field, including CEO stints at Quantum Dot Corp.,

Targesome, Epic Therapeutics, Metra Biosystems and StemCells (formerly CytoTherapeutics). **R. Douglas Armstrong** is stepping down as Aastron's CEO after 15 years; he will continue as chairman of the board for the remainder of his term.

PeriCor Therapeutics (New York) has named **Robert L. Engler** to its board of directors. Dr. Engler is an emeritus professor of medicine at the University of California, San Diego School of Medicine and also serves as chief medical advisor at Cadium Therapeutics. He is currently a member of the boards of directors of Halozyme Therapeutics and Coda Genomics.

Jack Goldstein has joined the board of directors of Illumina (San Diego, CA, USA). Dr. Goldstein was most recently president and COO of Chiron until its acquisition by Novartis in April. Prior to Chiron, he spent two years as a general partner at Windamere Venture Partners preceded by four years at Applied Imaging, first as president and CEO and then later as chairman.

ForteBio (Menlo Park, CA, USA) has named **K. Peter Hirth** to its board of directors. Dr. Hirth is cofounder and CEO of Plexxikon. He was previously president of Sugen until the sale of the company to Pharmacia. In addition, ForteBio announced the appointment of **Bernelle H. Saperstein** as vice president, manufacturing operations, a new position. She joins the company from BD-Immunocytometry Systems, where she was director, reagent operations.

Robert J. Janosky has been appointed NanoInk's (Skokie, IL, USA) president and COO. Mr.

Janosky served most recently as vice president, manufacturing at Cubist Pharmaceuticals. Previously, at Warner Lambert, he was vice president, manufacturing and president and general manager of the company's Puerto Rico location.

Transport Pharmaceuticals (Framingham, MA, USA) has named **Sean Moran** CFO. Mr. Moran previously served as CFO for Sontra Medical, SatCon Technology and Anika Therapeutics.

Chelsea Therapeutics International (Charlotte, NC, USA) has appointed **Keith W. Schmidt** vice president of marketing and sales. Mr. Schmidt was previously responsible for global prelaunch marketing preparation and life cycle planning for Pegasys at Hoffmann-La Roche.

John L. Tonkinson has been named vice president, business development at diagnostic developer HistoRx (New Haven, CT, USA). Dr. Tonkinson was most recently director of business development at Epitome BioSystems, and previously served as director of sales and scientific services at Schleicher & Schuell BioScience.



Charles White (left) has been appointed chief business officer at Nereus Pharmaceuticals (San Diego, CA, USA). He has over 25 years business development and marketing experience

in the industry, most recently as vice president of biotech business development at Organon. Previously, Dr. White served as vice president at Diosynth and at its predecessors, Corning Bio and Covance Biotechnology Services.

Enterprise Partners Venture Capital (San Diego, CA, USA) has announced that **Kleanthis G. Xanthopoulos** will join the firm by year-end as a managing director, after completing his transition from Anadys Pharmaceuticals. Dr. Xanthopoulos is the founder of Anadys, and has served as president, CEO and as a director since May 2000. From 1997 to 2000 he held a variety of positions at Aurora Biosciences, including vice president, genomics & molecular biology. He will remain on Anadys's board of directors.